EyePoint's decline following positive data makes no sense, says analyst
Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...
Investing on MSN3h
EyePoint Pharmaceuticals stock sinks following clinical trial results
Investing.com -- Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ: EYPT) fell 21% today, diverging from the company's recent announcement of positive results from the Phase 2 VERONA clinical ...
Hosted on MSN1h
NASA Shares Worrying Images Of US East Coast Engulfed By Smoke From Canadian Wildfires
The air quality index measures PM2.5, less than 2.5 microns particles, to determine the intensity of air pollution in cities.
DURAVYU shows promise in Phase 2 trial for eye disease
WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...
Bangkok Post on MSN4h
Pollution control areas to be designated
The Bangkok Metropolitan Administration (BMA) has authorised all 50 district offices to announce pollution control areas to ...
The 5 Best Dyson Vacuums That Offer Superior Cleaning On Every Surface
To find the best Dyson vacuums of 2025, we researched and analyzed the most popular models on the market. Here are our top ...